• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ESCITALOPRAM Drug Record

  • Summary
  • Interactions
  • Claims
  • ESCITALOPRAM chembl:CHEMBL1508 Approved

    Alternate Names:

    CIPRALEX
    LU-26-054
    ESCITALOPRAM
    (+)-CITALOPRAM
    S(+)-CITALOPRAM
    CIPRALEX®
    S-(+)-CITALOPRAM
    ESCITALOPRAMUM
    LEXAPRO
    ENTACT
    LEXAPRO®
    LU-26-054-0
    (S)-CITALOPRAM
    drugbank:01175
    chemidplus:128196-01-0
    chembl:CHEMBL1508
    rxcui:321988
    pubchem.compound:146570

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidepressant
    Drug Class antidepressive agents
    Year of Approval 2002
    (3 More Sources)

    Publications:

    Brasch-Andersen C et al., 2011, A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C)., Eur J Clin Pharmacol
    Sanchez C et al., 2014, A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?, Int Clin Psychopharmacol
    Kuo HW et al., 2013, CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions., Pharmacogenomics
    Perroud N et al., 2009, Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project., Neuropsychopharmacology
    Powell TR et al., 2013, Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response., Eur Neuropsychopharmacol
    Ji Y et al., 2011, Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics., Clin Pharmacol Ther
    Uher R et al., 2009, Genetic predictors of response to antidepressants in the GENDEP project., Pharmacogenomics J
    Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
    Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology
    Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
    Fabre et al., [Mechanisms of action of antidepressants: new data from Escitalopram]., Encephale
    Bareggi et al., 2007, The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders., Expert Opin Drug Metab Toxicol
    Zhong et al., 2009, An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant., Neurosci. Lett.
    Owens et al., 2001, Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine., Biol. Psychiatry
    Waugh et al., 2003, Escitalopram : a review of its use in the management of major depressive and anxiety disorders., CNS Drugs
    Sánchez et al., 2003, Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities., Psychopharmacology (Berl.)
    Burke, 2002, Escitalopram., Expert Opin Investig Drugs
    Owens et al., [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine]., Encephale
    Gupta M et al., 2016, TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics., Mol Psychiatry
    Tammiste A et al., 2013, Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression., J Psychopharmacol
  • ESCITALOPRAM   BMP5

    Interaction Score: 6.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23926243


    Sources:
    PharmGKB

  • ESCITALOPRAM   TSPAN5

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26903268


    Sources:
    PharmGKB

  • ESCITALOPRAM   ERICH3

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26903268


    Sources:
    PharmGKB

  • ESCITALOPRAM   GLDC

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21107318


    Sources:
    PharmGKB

  • ESCITALOPRAM   RFK

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ESCITALOPRAM   TPH1

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 23221997 19590397


    Sources:
    PharmGKB

  • ESCITALOPRAM   IL11

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23142150


    Sources:
    PharmGKB

  • ESCITALOPRAM   SLC6A4

    Interaction Score: 0.73

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Cipralex, escitalopram,Lexapro
    Novel drug target Established target

    PMIDs:
    12876551 17916059 19616061 11543737 12665392 12719960 12387707 12232544 24424469


    Sources:
    TdgClinicalTrial TEND

  • ESCITALOPRAM   GRK5

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ESCITALOPRAM   FKBP5

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ESCITALOPRAM   HTR2C

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    21614492 24424469


    Sources:
    PharmGKB

  • ESCITALOPRAM   BDNF

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19641488


    Sources:
    PharmGKB

  • ESCITALOPRAM   HTR1B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ESCITALOPRAM   HTR2A

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19365399 24424469


    Sources:
    PharmGKB

  • ESCITALOPRAM   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC FDA

  • ESCITALOPRAM   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23859573


    Sources:
    PharmGKB

  • ESCITALOPRAM   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ESCITALOPRAM   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • TEND: ESCITALOPRAM

    • Version: 01-August-2011

    Alternate Names:
    ESCITALOPRAM Primary Drug Name

    Drug Info:
    Year of Approval 2002
    Drug Class antidepressive agents

    Publications:

  • TdgClinicalTrial: ESCITALOPRAM

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidepressant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: escitalopram

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Brasch-Andersen C et al., 2011, A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C)., Eur J Clin Pharmacol
    Gupta M et al., 2016, TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics., Mol Psychiatry
    Perroud N et al., 2009, Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project., Neuropsychopharmacology

  • TTD: Escitalopram

    • Version: 2020.06.01

    Alternate Names:
    D08RBC TTD Drug ID

    Drug Info:

    Publications:

  • DTC: ESCITALOPRAM

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1508 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1508

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Escitalopram

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21